Mediwound reports third quarter 2024 financial results and provides company update

Escharex ind submission by year-end; phase 3 study to begin shortly thereafter; kol event set for january 8, 2025 fda approves nexobrid for pediatric use $25 million financing and €16.25 million eic funding strengthen cas h runway to profitability nexobrid product revenue meets expectations; demand exceeds capacity as new manufacturing facility commissioning underway conference call today, november 26 at 8:30 a.m. eastern time yavne, israel, nov. 26, 2024 (globe newswire) -- mediwound ltd.
MDWD Ratings Summary
MDWD Quant Ranking